Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.74 |
| ▸ | CA2 | P00918 | 6/20 | 0.74 |
| ▸ | CA12 | O43570 | 5/20 | 0.74 |
| ▸ | CA9 | Q16790 | 5/20 | 0.74 |
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.74 |
| ▸ | CA6 | P23280 | 4/20 | 0.74 |
| ▸ | CA5A | P35218 | 4/20 | 0.74 |
| ▸ | CA7 | P43166 | 4/20 | 0.74 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.74 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | CA4 | P22748 | 1/20 | 0.74 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.74 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.74 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.74 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.74 |
| ▸ | APP | P05067 | 9/20 | 0.66 |
| ▸ | AQP1 | P29972 | 1/20 | 0.61 |
| ▸ | TEX264 | Q9Y6I9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422550 | 0.93 | CA12 (0.68) | CA1CA2CA12CA9CISD1 | |
| SCHEMBL22971174 | 0.93 | CA12 (0.67) | CA1CA2CA12CA9CISD1 | |
| SCHEMBL12418669 | 0.92 | CISD1 (0.69) | CA1CA2CA12CA9CISD1 | |
| SCHEMBL22970894 | 0.92 | CISD1 (0.68) | CA1CA2CA12CA9CISD1 | |
| SCHEMBL22971058 | 0.92 | CISD1 (0.68) | CA1CA2CA12CA9CISD1 | |
| SCHEMBL12418670 | 0.91 | CISD1 (0.70) | CA1CA2CA12CA9CISD1 | |
| SCHEMBL2956412 | 0.91 | CISD1 (0.65) | CA1CA2CA12CA9CISD1 | |
| SCHEMBL11821548 | 0.91 | APP (0.67) | CA1CA2CA12CA9CISD1 | |
| SCHEMBL2949798 | 0.91 | CA12 (0.76) | CA1CA2CA12CA9CISD1 | |
| SCHEMBL230392 | 0.91 | APP (0.79) | CA1CA2CA12CA9CISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137875-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | OTOLANUM AG (CH) | 2021-05-13 | — | — | US | claimed |
| US-20180360797-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | EBERHARD-KARLS-UNIVERSITAT TUBINGEN UNIVERSITATSKLINIKUM (DE) | 2018-12-20 | — | — | US | claimed |
| WO-2017042314-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF POST-TRAUMATIC EPILEPSIES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-16 | — | — | WO | claimed |
| US-20160271098-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | EBERHARD-KARLS-UNIVERSITAT TUBINGEN UNIVERSITATSKLINIKUM (DE) | 2016-09-22 | — | — | US | claimed |
| US-20150044200-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | OTOLANUM AG (CH) | 2015-02-12 | — | — | US | claimed |
| EP-2790686-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | Auris Medical AG (CH) | 2014-10-22 | — | — | EP | claimed |
| WO-2013087090-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | AURIS MEDICAL AG (CH) | 2013-06-20 | — | — | WO | claimed |
| US-20120234721-A1 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-09-20 | — | — | US | claimed |
| US-20120108640-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-05-03 | — | — | US | claimed |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. | 2009-08-27 | — | — | US | claimed |
| EP-1874286-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | NEUROTHERAPEUTICS PHARMA INC (US) | 2009-07-01 | — | — | EP | claimed |
| EP-1951702-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1937242-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-07-02 | — | — | EP | claimed |
| EP-1874286-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | Neurotherapeutics Pharma LLC (US) | 2008-01-09 | — | — | EP | claimed |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | NEUROTHERAPEUTICS PHARMA, L.L.C. | 2007-06-28 | — | — | US | claimed |
| WO-2007047447-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| WO-2007047698-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| WO-2006110187-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-10-19 | — | — | WO | claimed |
| US-20060089350-A1 | Methods and compositions for the treatment of neuropsychiatric disorders | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-04-27 | — | — | US | claimed |
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20210137875-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | OTOLANUM AG (CH) | 2021-05-13 | — | — | US | disclosed |
| EP-2790686-B1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | Zilentin AG (CH) | 2021-03-10 | — | — | EP | disclosed |
| US-10709682-B2 | Treatment of tinnitus through modulation of chloride co-transporter NKCC1 in the auditory system | OTOLANUM AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3004353-B1 | BUMETANIDE FOR TREATING NEURODEGENERATIVE DISEASES WITH PARKINSONIAN SYNDROMES | B & A THERAPEUTICS INMED (FR) | 2019-04-10 | — | — | EP | disclosed |
| US-10201507-B2 | Modulators of intracellular chloride concentration for treating fragile X syndrome | NEUROCHLORE (FR) | 2019-02-12 | — | — | US | disclosed |
| EP-3083959-B1 | INHIBITORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING DOWN SYNDROME | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2019-02-06 | — | — | EP | disclosed |
| US-20180360797-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | EBERHARD-KARLS-UNIVERSITAT TUBINGEN UNIVERSITATSKLINIKUM (DE) | 2018-12-20 | — | — | US | disclosed |
| US-9974763-B2 | Modulators of intracellular chloride concentration for treating neurodegenerative diseases with Parkinsonian Syndromes | B&A THERAPEUTICS (FR) | 2018-05-22 | — | — | US | disclosed |
| US-9822368-B2 | Modulators of intracellular chloride concentration for treating down syndrome | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-11-21 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2523661-B1 | NKCC INHIBITORS FOR THE TREATMENT OF AUTISM | INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) (FR) | 2017-05-10 | — | — | EP | disclosed |
| WO-2017042314-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF POST-TRAUMATIC EPILEPSIES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-16 | — | — | WO | disclosed |
| US-9592214-B2 | Compounds for the treatment of autism in a baby child | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-03-14 | — | — | US | disclosed |
| US-20160312229-A1 | Modulators of Intracellular Chloride Concentration for Treating Down Syndrome | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2016-10-27 | — | — | US | disclosed |
| EP-3083959-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING DOWN SYNDROME | Fondazione Istituto Italiano Di Tecnologia (IT) | 2016-10-26 | — | — | EP | disclosed |
| US-20160271098-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | EBERHARD-KARLS-UNIVERSITAT TUBINGEN UNIVERSITATSKLINIKUM (DE) | 2016-09-22 | — | — | US | disclosed |
| US-9415028-B2 | Compounds for the treatment of autism | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-08-16 | — | — | US | disclosed |
| US-20160106693-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING NEURODEGENERATIVE DISEASES WITH PARKINSONIAN SYNDROMES | NANTES UNIVERSITE (FR) | 2016-04-21 | — | — | US | disclosed |
| EP-3004353-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING NEURODEGENERATIVE DISEASES WITH PARKINSONIAN SYNDROMES | B & A Therapeutics INMED (FR) | 2016-04-13 | — | — | EP | disclosed |
| US-9248131-B2 | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2016-02-02 | — | — | US | disclosed |
| US-9248131-B2 | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150335600-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING FRAGILE X SYNDROME | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2015-11-26 | — | — | US | disclosed |
| EP-2919769-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING FRAGILE X SYNDROME | Neurochlore (FR) | 2015-09-23 | — | — | EP | disclosed |
| US-20150224108-A1 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE | UNIV ARIZONA STATE (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150224108-A1 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE | UNIV ARIZONA STATE (US) | 2015-08-13 | — | — | US | disclosed |
| WO-2015091857-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING DOWN SYNDROME | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-06-25 | — | — | WO | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150044200-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | OTOLANUM AG (CH) | 2015-02-12 | — | — | US | disclosed |
| WO-2014191471-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING NEURODEGENERATIVE DISEASES WITH PARKINSONIAN SYNDROMES | NEUROCHLORE (FR) | 2014-12-04 | — | — | WO | disclosed |
| EP-2808391-A1 | Modulators of intracellular chloride concentration for treating neurodegenerative diseases with parkinsonian syndromes | Neurochlore (FR) | 2014-12-03 | — | — | EP | disclosed |
| EP-2790686-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | Auris Medical AG (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-8835491-B2 | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835491-B2 | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-09-16 | — | — | US | disclosed |
| WO-2014076235-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING FRAGILE X SYNDROME | NEUROCHLORE (FR) | 2014-05-22 | — | — | WO | disclosed |
| EP-2732815-A1 | Modulators of intracellular chloride concentration for treating fragile X syndrome | Neurochlore (FR) | 2014-05-21 | — | — | EP | disclosed |
| US-20140080910-A1 | COMPOUNDS FOR THE TREATMENT OF AUTISM IN A BABY CHILD | NEUROCHLORE (FR) | 2014-03-20 | — | — | US | disclosed |
| WO-2013087090-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | AURIS MEDICAL AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| US-20130022622-A1 | COMPOUNDS FOR THE TREATMENT OF AUTISM | CHU DE BREST (FR) | 2013-01-24 | — | — | US | disclosed |
| EP-2523661-A1 | COMPOUNDS FOR THE TREATMENT OF AUTISM | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2012-11-21 | — | — | EP | disclosed |
| US-20120252894-A1 | COMPOUNDS FOR ALLEVIATING PAIN AND STRESS IN FETUS AND NEWBORN | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCH MEDICALE (INSERM) (FR) | 2012-10-04 | — | — | US | disclosed |
| US-20120234721-A1 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120108640-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| CN-102341380-A | Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use | NEUROTHERAPEUTICS PHARMA INC | 2012-02-01 | — | — | CN | disclosed |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2389371-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | Neurotherapeutics Pharma, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8008283-B2 | Methods and compositions for the treatment of neuropsychiatric disorders | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| WO-2011086126-A1 | COMPOUNDS FOR THE TREATMENT OF AUTISM | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-07-21 | — | — | WO | disclosed |
| US-20110172195-A1 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE | ARIZONA BOARD OF REG. ON BEHALF OF THE UNIV. OF AZ (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172195-A1 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE | ARIZONA BOARD OF REG. ON BEHALF OF THE UNIV. OF AZ (US) | 2011-07-14 | — | — | US | disclosed |
| US-7906555-B2 | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906555-B2 | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2011-03-15 | — | — | US | disclosed |
| WO-2010085352-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. | 2009-08-27 | — | — | US | disclosed |
| EP-1874286-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | NEUROTHERAPEUTICS PHARMA INC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080221169-A1 | 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels; brain trauma, head trauma, eye disorder, pulmonary disorder, lung disease, vascular disease, kidney disease, heavy metal toxicity, Alzheimer's disease, tumor, and cancer | ARIZONA BOARD OF REG. ON BEHALF OF THE UNIV. OF AZ (US) | 2008-09-11 | — | — | US | disclosed |
| EP-1951702-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1937242-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1874286-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | Neurotherapeutics Pharma LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | NEUROTHERAPEUTICS PHARMA, L.L.C. | 2007-06-28 | — | — | US | disclosed |
| WO-2007047698-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047447-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006110187-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060089350-A1 | Methods and compositions for the treatment of neuropsychiatric disorders | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-04-27 | — | — | US | disclosed |
| US-20060089350-A1 | Methods and compositions for the treatment of neuropsychiatric disorders | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (24 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160312229-A1 | Modulators of Intracellular Chloride Concentration for Treating Down Syndrome | SLC8B1, SLC6A1, SLC6A12 | CA1 3832/4885CA2 302/4885CA12 4590/4885 |
| US-20180360797-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | SLC6A1, SLC6A11, SLC6A13 | CA1 1240/4885CA2 209/4885CA12 1273/4885 |
| US-20120234721-A1 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS | AQP4, AVPR2, AQP1 | CA1 559/4885CA2 708/4885CA12 1656/4885 |
| US-20160106693-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING NEURODEGENERATIVE DISEASES WITH PARKINSONIAN SYNDROMES | SLC6A1, SLC18A3, SLC8B1 | CA1 3471/4885CA2 573/4885CA12 4248/4885 |
| US-20080221169-A1 | 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels; brain trauma, head trauma, eye disorder, pulmonary disorder, lung disease, vascular disease, kidney disease, heavy metal toxicity, Alzheimer's disease, tumor, and cancer | AQP4, AQP3, AQP1 | CA1 223/4885CA2 12/4885CA12 372/4885 |
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA1 988/4885CA2 489/4885CA12 1338/4885 |
| US-20160271098-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | SLC6A1, SLC6A11, SLC6A13 | CA1 1161/4885CA2 209/4885CA12 1146/4885 |
| US-20150335600-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION FOR TREATING FRAGILE X SYNDROME | SLC8B1, SLC6A1, SLC8A1 | CA1 3796/4885CA2 924/4885CA12 4639/4885 |
| US-20060089350-A1 | Methods and compositions for the treatment of neuropsychiatric disorders | SLC1A2, SLC18A2, GRIN2C | CA1 490/4885CA2 308/4885CA12 1092/4885 |
| US-10201507-B2 | Modulators of intracellular chloride concentration for treating fragile X syndrome | SLC8B1, SLC6A1, SLC8A1 | CA1 3796/4885CA2 924/4885CA12 4639/4885 |
| US-20210137875-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | SLC6A1, SLC6A13, SLC6A11 | CA1 1024/4885CA2 256/4885CA12 1181/4885 |
| US-20150224108-A1 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE | AQP1, AQP4, AQP3 | CA1 1196/4885CA2 168/4885CA12 1649/4885 |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA1 1022/4885CA2 471/4885CA12 1444/4885 |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA1 988/4885CA2 489/4885CA12 1338/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | CA1 701/4885CA2 388/4885CA12 1049/4885 |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | ABCG2, ABCB1, TRPV1 | CA1 1755/4885CA2 1572/4885CA12 2528/4885 |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | AQP4, AVPR2, AQP1 | CA1 559/4885CA2 708/4885CA12 1656/4885 |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | SLC6A2, SLC1A2, SLC18A2 | CA1 847/4885CA2 408/4885CA12 1302/4885 |
| US-20120108640-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | SLC1A2, SLC18A2, GRIN2C | CA1 490/4885CA2 308/4885CA12 1092/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA1 1762/4885CA2 1422/4885CA12 2583/4885 |
| US-20140080910-A1 | COMPOUNDS FOR THE TREATMENT OF AUTISM IN A BABY CHILD | SLC6A1, SLC6A11, SLC6A13 | CA1 608/4885CA2 665/4885CA12 1027/4885 |
| US-20110172195-A1 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE | AQP1, AQP4, AQP3 | CA1 1196/4885CA2 168/4885CA12 1649/4885 |
| US-10709682-B2 | Treatment of tinnitus through modulation of chloride co-transporter NKCC1 in the auditory system | SLC6A1, SLC6A11, SLC6A13 | CA1 1239/4885CA2 208/4885CA12 1270/4885 |
| US-20150044200-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | SLC6A1, SLC6A11, SLC6A13 | CA1 1239/4885CA2 208/4885CA12 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.